Online citations, reference lists, and bibliographies.
← Back to Search

Immunization With A Soluble Recombinant HIV Protein Entrapped In Biodegradable Microparticles Induces HIV-specific CD8+ Cytotoxic T Lymphocytes And CD4+ Th1 Cells.

A. Moore, P. Mcguirk, S. Adams, W. Jones, J. P. Mcgee, D. O'hagan, K. Mills
Published 1995 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
One of the major obstacles to the development of successful recombinant vaccines against human immunodeficiency virus (HIV) and other intracellular pathogens is the identification of a safe and effective vaccine delivery system for the induction of cell mediated immunity with soluble protein antigens. In this study it was demonstrated that immunization with a recombinant HIV envelop (env) protein entrapped in biodegradable poly(lactide-co-glycolide) (PLG) microparticles induced consistent HIV-specific CD4+ and CD8+ T-cell responses in mice. Major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes (CTL) responses were detected following a single systemic immunization with gp120 entrapped microparticles and when given by the intranasal (i.n.) route induced HIV-specific CD8+ CTL and secretory IgA. Furthermore immunization with gp120 entrapped in microparticles generated CD4+ T cells that secreted moderate to high levels of IFN-gamma. Therefore, PLG microparticles are a safe and effective means of delivering antigen to the appropriate processing site for the generation of class I-restricted CTL, and are also capable of inducing Th1 cells.
This paper references
10.1038/344873A0
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs
H. Takahashi (1990)
10.1073/PNAS.88.3.991
Peptide-induced antiviral protection by cytotoxic T cells.
M. Schulz (1991)
10.1089/AID.1992.8.1765
The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants.
R. Bomford (1992)
10.1016/0264-410X(89)90156-4
Microparticles as potentially orally active immunological adjuvants.
D. O'hagan (1989)
Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.
T. Gajewski (1991)
Distinct regulation of lymphokine production is found in fresh versus in vitro primed murine helper T cells.
A. Weinberg (1990)
10.1016/0161-5890(91)90076-V
Biodegradable microspheres as a vaccine delivery system.
J. Eldridge (1991)
10.1016/0022-1759(92)90032-O
Preparative separation of foreign antigens for highly efficient presentation to T cells in vitro.
K. Katrak (1992)
Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles.
G. Layton (1993)
10.1016/0167-5699(92)90158-4
The role of nasopharyngeal lymphoid tissue.
C. Kuper (1992)
10.1128/IAI.61.8.3190-3198.1993
Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity.
K. Redhead (1993)
10.1084/JEM.181.4.1285
Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor
B. Mahon (1995)
10.1038/NM0195-59
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
S. Rowland-Jones (1995)
10.1038/345622A0
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
P. Berman (1990)
10.1038/342561A0
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
K. Deres (1989)
Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
J. Wu (1992)
Secretory antibody response to viral vaccines.
P. Ogra (1990)
10.1016/S0065-2776(08)60652-5
Heterogeneity of cytokine secretion patterns and functions of helper T cells.
T. Mosmann (1989)
10.1126/SCIENCE.8023139
Cytokine patterns during the progression to AIDS.
T. Mosmann (1994)
10.1016/0264-410X(93)90011-L
Biodegradable microparticles for oral immunization.
D. O'hagan (1993)
10.1126/SCIENCE.1360702
Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein.
T. Lehner (1992)
10.1084/JEM.171.5.1815
Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide
P. Aichele (1990)
10.1128/JVI.64.5.2290-2297.1990
Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals.
S. Sutjipto (1990)
10.1073/PNAS.88.2.542
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
M. Girard (1991)
10.1016/0008-8749(89)90011-7
Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses.
J. L. Grun (1989)
10.1084/JEM.163.6.1477
Extensive diversity in the recognition of influenza virus hemagglutinin by murine T helper clones
K. Mills (1986)
10.1126/SCIENCE.8023143
Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals.
C. Graziosi (1994)
HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1.
K. Mills (1990)
10.1128/JVI.65.1.220-224.1991
Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells.
R. Hom (1991)
10.1097/00002030-198901001-00015
T‐cell strategies in AIDS vaccines: MHC‐restricted T‐cell responses to HIV proteins
K. Mills (1989)
10.1126/SCIENCE.8493576
Protection against vaginal SIV transmission with microencapsulated vaccine.
P. Marx (1993)
10.1038/354453A0
Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition
R. Phillips (1991)
10.1073/PNAS.89.17.8308
Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo.
S. Raychaudhuri (1992)
Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles.
F. Zhou (1992)
Viruses and the cellular immune response
D. Thomas (1993)
10.1159/000319112
T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation.
G. Shearer (1992)
10.1093/INFDIS/165.6.1012
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1.
M. Clerici (1992)
10.1007/978-3-642-78536-8_12
Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines.
E. J. Stott (1994)
10.1126/SCIENCE.256.5064.1687
Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.
P. Fultz (1992)
Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.
K. Maloy (1994)



This paper is referenced by
Human Dendritic Cells: Cell Culture Models for Studies of Particulate Antigen Formulations in vitro
C. Foged (2003)
10.1016/S0169-409X(01)00169-7
Manipulating the immune system: humoral versus cell-mediated immunity.
E. McNeela (2001)
10.1016/S0169-409X(97)00053-7
New advances in microsphere-based single-dose vaccines.
Langer (1997)
10.1016/j.ijpharm.2016.08.059
PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model.
P. Li (2016)
10.1016/B978-012088403-2/50009-5
Microparticles as vaccine delivery systems
D. O'hagan (2006)
10.1163/156856299X00892
Intranasal immunization against influenza virus using polymeric particles.
D. Lemoine (1999)
10.1016/J.VACCINE.2003.10.035
A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4.
J. T. Evans (2004)
10.22092/ARI.2008.103739
PREPARATION AND IN-VITRO EVALUATION OF SODIUM ALGINATE MICROSPHERES CONTAINING DIPHTHERIA TOXOID AS NEW VACCINE DELIVERY
A. Mokaram (2008)
10.1021/JS970174N
Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine.
M. Singh (1997)
PLGA nanopartikler som vaksinebærere
Karina Lundvang Sævareid (2009)
10.1097/00006454-200206000-00004
Childhood vaccinations and risk of asthma
F. Destefano (2002)
10.1016/J.ADDR.2004.09.003
Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.
Wenlei Jiang (2005)
10.1016/S0168-3659(00)00270-4
Controlled release of macromolecules from PLA microspheres: using porous structure topology.
T. Ehtezazi (2000)
10.1080/10611860701637966
Rational design of nasal vaccines
B. Slütter (2008)
10.1201/B19038-51
Emulsion-Solvent System for Drug Delivery
W. Obeidat (2015)
10.1111/j.1365-2222.2007.02922.x
Intranasal vaccination with poly(lactide‐co‐glycolide) microparticles containing a peptide T of Ole e 1 prevents mice against sensitization
E. Marazuela (2008)
10.31274/ETD-180810-561
In vitro and in vivo evaluation of novel biodegradable polymer adjuvants for vaccine delivery
Wilson Welder (2009)
10.1016/B978-0-323-39981-4.00014-2
Microparticles for Vaccine Delivery
N. Mody (2017)
Thl / Th 2 cell dichotomy in acquired immunity to Bordetellapertussis : variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Thl , Th 2 or
Thọ ()
10.1002/BIOT.200600246
Putting microbes to work: Dairy fermentation, cell factories and bioactive peptides. Part I: Overview
M. Hayes (2007)
10.1186/s12929-015-0195-2
Preparation, characterization and immunological evaluation: canine parvovirus synthetic peptide loaded PLGA nanoparticles
S. Derman (2015)
10.2174/157341311794653541
Nanocarriers for Transmucosal Vaccine Delivery
S. Jain (2011)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.1016/J.VACCINE.2005.01.149
Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.
S. P. Mossman (2005)
10.1007/978-0-387-33785-2_6
Ex Vivo –Generated Dendritic Cells for ClinicalTrials versus In Vivo Targeting to Dendritic Cells: Critical Issues
J. F. Jacobs (2007)
10.1016/S0168-3659(02)00276-6
Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens.
M. Murillo (2002)
10.1016/J.JCONREL.2005.10.010
Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
J. Kazzaz (2006)
10.1016/J.VACCINE.2006.04.011
Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles.
R. Rajkannan (2006)
10.1016/S0264-410X(99)00522-8
Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
D. O'hagan (2000)
10.1016/0022-1759(96)00096-8
Mucosal immunization with a measles virus CTL epitope encapsulated in biodegradable PLG microparticles.
C. Partidos (1996)
10.1016/j.ijpharm.2019.05.012
Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.
Shailendra B Tallapaka (2019)
10.1201/9780203910337-56
ALZAMER DepotTM Bioerodible Polymer Technology
J. Wright (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar